Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development

Set Alert for Research & Development

Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate

Phase II data in two rare hematological disorders show potential for transformative therapeutic benefit, according to analysts. The company awaits more results for further confirmation.

Clinical Trials Business Strategies

Pipeline Watch: ASCO Readouts Dominate

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Clinical Trials

AZ’s Danicopan Could Protect Ultomiris After Pivotal Combination Success In PNH

The major’s factor D inhibitor has increased hemoglobin in a subset of paroxysmal nocturnal hemoglobinuria patients when added to a C5 inhibitor, paving the way for an approval that could help protect Ultomiris from competition.

Clinical Trials Rare Diseases

Chinese Language Podcast: ASCO专集

J&J and Legend’s Carvykti shines at ASCO while Junshi provides PD-1 antibody toripalimab updates. Alongside, ADCs from Biokin, BlissBio also steps into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stands out in this special ASCO episode of the latest Chinese-language podcast. 

China Clinical Trials

Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.

ASCO Interviews

Shionogi Renews 10-Year Goal After Infectious Disease Success

Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals earlier, its new strategy covers HIV and COVID-19 products with more new products to be launched.

Commercial Coronavirus COVID-19

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.

ASCO ImmunoOncology

FibroGen Misses In First Of Two Pivotal DMD Trials

The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.

Clinical Trials Business Strategies

Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO

Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy. 

ASCO Clinical Trials

Pipeline Watch: 11 Approvals And 12 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats

The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

ASCO Clinical Trials

ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill

The company’s TIGIT data are strong enough for a phase 3 trial to be launched, ASCO learns.

ASCO Clinical Trials
UsernamePublicRestriction

Register